Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Recombinant CHRM2/CM2 Antibody - Primary antibody, specific to CHRM2, Rabbit IgG

  • ExactAb™
  • Recombinant
  • Validated
  • 0.3 mg/mL
Features and benefits
  • Short Overview:

    Recombinant; Rabbit anti Human Muscarinic Acetylcholine Receptor 2/CM2 Antibody; WB; Unconjugated

  • Species reactivity(Reacts with): Human,Mouse,Rat
  • Isotype: Rabbit IgG
    Application:
  • WB
Item Number
Ab116536
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab116536-10μl
10μl
In stock
$86.90
Ab116536-50μl
50μl
In stock
$249.90
Ab116536-100μl
100μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$399.90
Ab116536-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,699.90
Add to Wish List Compare
Bulk Order  DATASHEET

Recombinant; Rabbit anti Human Muscarinic Acetylcholine Receptor 2/CM2 Antibody; WB; Unconjugated

View related series
Accession#:P08172 CHRM2 CM2 Gene ID:1129 Muscarinic Acetylcholine Receptor 2

Basic Description

Product NameRecombinant CHRM2/CM2 Antibody - Primary antibody, specific to CHRM2, Rabbit IgG
Synonyms7TM receptor; cholinergic receptor, muscarinic 2; CHRM2; FLJ43243; HM2; mAChR M2; MGC120006; MGC120007; muscarinic acetylcholine receptor M2; muscarinic M2 receptor; 7TM receptor antibody; Acetylcholine receptor, muscarinic, 2 antibody; AChR antibody; Acm
Specifications & PurityExactAb™, Validated, Recombinant, 0.3 mg/mL
Host speciesRabbit
SpecificityCHRM2
ImmunogenA synthetic peptide derived from human Muscarinic Acetylcholine Receptor 2 (AA 165-178).
Positive ControlWB: K562, Hep G2, HeLa, NIH/3T3 and C6 cell lysates.
ConjugationUnconjugated
GradeExactAb™, Recombinant, Validated
Product Description

Rabbit anti Human Muscarinic Acetylcholine Receptor 2/CM2 Antibody, Recombinant, could be used for WB and so on.
Application:
WB: 1/500-1/1000
Protein function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition.

Product Properties

IsotypeRabbit IgG
SDS-PAGE150 kDa
Purification MethodImmunogen affinity purified
FormLiquid
Concentration0.3 mg/mL
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant Muscarinic Acetylcholine Receptor 2/CM2 Antibody (Ab116536) - Western Blot
All lanes: Recombinant Muscarinic Acetylcholine Receptor 2/CM2 Antibody (Ab116536) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 52 kDa
Observed band size: 49 kDa
Exposure time: 10.5 s


Associated Targets

CHRM2 Tclin Muscarinic acetylcholine receptor M2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Application

ApplicationDilution info
WB

1/500-1/1000

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot NumberCertificate TypeDateItem
ZJ24F0202747Certificate of AnalysisFeb 06, 2024 Ab116536
ZJ24F0202748Certificate of AnalysisFeb 06, 2024 Ab116536

Related Documents

 SDS

 Specification Sheet

FAQs and Articles

FAQ
Protocol and tips for whole mount immunohistochemical staining
Categories: Protocols
Tags:
Antibody Primary antibody Recombinant antibody IHC Immunohistochemical staining Whole mount immunohistochemical staining Epitope Tag Antibodies

References

1. Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM.  (1998)  Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors..  Br J Pharmacol,  125  (7): (1413-20).  [PMID:9884068]
2. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ.  (1987)  Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors..  EMBO J,  6  (13): (3923-9).  [PMID:3443095]
3. Bonner TI, Buckley NJ, Young AC, Brann MR.  (1987)  Identification of a family of muscarinic acetylcholine receptor genes..  Science,  237  (4814): (527-32).  [PMID:3037705]
4. Froestl W, Mickel SJ, von Sprecher G, Diel PJ, Hall RG, Maier L, Strub D, Melillo V, Baumann PA, Bernasconi R et al..  (1995)  Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists..  J Med Chem,  38  (17): (3313-31).  [PMID:7650685]
5. Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA et al..  (2008)  Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity..  Bioorg Med Chem Lett,  18  (12): (3611-5).  [PMID:18490160]
6. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Kobilka BK, Haga T et al..  (2012)  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist..  Nature,  482  (7386): (547-51).  [PMID:22278061]
7. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, Sexton PM et al..  (2013)  Activation and allosteric modulation of a muscarinic acetylcholine receptor..  Nature,  504  (7478): (101-6).  [PMID:24256733]
8. Cappelli A, Manini M, Valenti S, Castriconi F, Giuliani G, Anzini M, Brogi S, Butini S, Gemma S, Campiani G et al..  (2013)  Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds..  Eur J Med Chem,  63  (3): (85-94).  [PMID:23466604]
9. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al..  (2008)  cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia..  J Med Chem,  51  (22): (7094-8).  [PMID:18983139]
10. Coombs TC, Tanega C, Shen M, Wang JL, Auld DS, Gerritz SW, Schoenen FJ, Thomas CJ, Aubé J.  (2013)  Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315..  Bioorg Med Chem Lett,  23  (12): (3654-61).  [PMID:23642479]
11. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al..  (2012)  Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent..  J Med Chem,  55  (2): (903-13).  [PMID:22148921]
12. Theodoulou NH, Bamborough P, Bannister AJ, Becher I, Bit RA, Che KH, Chung CW, Dittmann A, Drewes G, Drewry DH et al..  (2016)  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition..  J Med Chem,  59  (4): (1425-39).  [PMID:25856009]
13. Croy CH, Schober DA, Xiao H, Quets A, Christopoulos A, Felder CC.  (2014)  Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors..  Mol Pharmacol,  86  (1): (106-15).  [PMID:24807965]
14. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, Hammer R.  (1993)  Ba 679 BR, a novel long-acting anticholinergic bronchodilator..  Life Sci,  52  (5-6): (537-44).  [PMID:8441333]
15. Gentry PR, Kokubo M, Bridges TM, Noetzel MJ, Cho HP, Lamsal A, Smith E, Chase P, Hodder PS, Niswender CM et al..  (2014)  Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)..  J Med Chem,  57  (18): (7804-10).  [PMID:25147929]
16. Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J et al..  (2010)  Spiroindolones, a potent compound class for the treatment of malaria..  Science,  329  (5996): (1175-80).  [PMID:20813948]
17. Hegde SS, Pulido-Rios MT, Luttmann MA, Foley JJ, Hunsberger GE, Steinfeld T, Lee T, Ji Y, Mammen MM, Jasper JR.  (2018)  Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues..  Pharmacol Res Perspect,  6  (3): (e00400).  [PMID:29736245]
18. Bucknell SJ, Ator MA, Brown AJH, Brown J, Cansfield AD, Cansfield JE, Christopher JA, Congreve M, Cseke G, Deflorian F et al..  (2020)  Structure-Based Drug Discovery of N-((R)-3-(7-Methyl-1H-indazol-5-yl)-1-oxo-1-(((S)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-d][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine..  J Med Chem,  63  (14): (7906-7920).  [PMID:32558564]
19. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD et al..  (2019)  3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma..  J Med Chem,  62  (15): (6876-6893).  [PMID:31282155]
20. Hansen JD, Correa M, Alexander M, Nagy M, Huang D, Sapienza J, Lu G, LeBrun LA, Cathers BE, Zhang W et al..  (2021)  CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia..  J Med Chem,  64  (4): (1835-1843).  [PMID:33591756]
21. Ch'ng SS, Walker AJ, McCarthy M, Le TK, Thomas N, Gibbons A, Udawela M, Kusljic S, Dean B, Gogos A.  (2020)  The Impact of Removal of Ovarian Hormones on Cholinergic Muscarinic Receptors: Examining Prepulse Inhibition and Receptor Binding..  Brain Sci,  10  (2): (589-97).  [PMID:32079174]
22. Takayuki Fukaya,Takeo Ishiyama,Satoko Baba,Shuji Masumoto.  (2013-09-21)  Identification of a novel benzoxazolone derivative as a selective, orally active 18 kDa translocator protein (TSPO) ligand..  Journal of medicinal chemistry,  56  ((20)): (8191-8195).  [PMID:24050790]
23. John A Christopher,Jason Brown,Andrew S Doré,James C Errey,Markus Koglin,Fiona H Marshall,David G Myszka,Rebecca L Rich,Christopher G Tate,Benjamin Tehan,Tony Warne,Miles Congreve.  (2013-03-23)  Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design..  Journal of medicinal chemistry,  56  ((9)): (3446-3455).  [PMID:23517028]
24. Glen RC, Martin GR, Hill AP, Hyde RM, Woollard PM, Salmon JA, Buckingham J, Robertson AD..  (1995)  Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties..  J Med Chem,  38  (18): (3566-3580).  [PMID:7658443]
25. Cao Y, Zhang M, Wu C, Lee S, Wroblewski ME, Whipple T, Nagy PI, Takács-Novák K, Balázs A, Torös S, Messer WS..  (2003)  Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders..  J Med Chem,  46  (20): (4273-4286).  [PMID:13678406]
26. Tumiatti V, Rosini M, Bartolini M, Cavalli A, Marucci G, Andrisano V, Angeli P, Banzi R, Minarini A, Recanatini M, Melchiorre C..  (2003)  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine..  J Med Chem,  46  (6): (954-966).  [PMID:12620072]
27. Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R, Heng R, Hiestand P, Jachez-Demange B, Loetscher P, Sparrer H, Schlapbach A, Waelchli R..  (2005)  Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis..  Bioorg Med Chem Lett,  15  (23): (5160-5164).  [PMID:16198561]
28. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S..  (2006)  An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression..  J Med Chem,  49  (11): (3116-3135).  [PMID:16722631]
29. Ulven T, Receveur JM, Grimstrup M, Rist Ø, Frimurer TM, Gerlach LO, Mathiesen JM, Kostenis E, Uller L, Högberg T..  (2006)  Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits..  J Med Chem,  49  (23): (6638-6641).  [PMID:17154491]
30. Watson RJ, Allen DR, Birch HL, Chapman GA, Galvin FC, Jopling LA, Knight RL, Meier D, Oliver K, Meissner JW, Owen DA, Thomas EJ, Tremayne N, Williams SC..  (2008)  Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives..  Bioorg Med Chem Lett,  18  (1): (147-151).  [PMID:18032038]
31. Grice CA, Tays KL, Savall BM, Wei J, Butler CR, Axe FU, Bembenek SD, Fourie AM, Dunford PJ, Lundeen K, Coles F, Xue X, Riley JP, Williams KN, Karlsson L, Edwards JP..  (2008)  Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity..  J Med Chem,  51  (14): (4150-4169).  [PMID:18588282]
32. Bridges TM, Brady AE, Kennedy JP, Daniels RN, Miller NR, Kim K, Breininger ML, Gentry PR, Brogan JT, Jones CK, Conn PJ, Lindsley CW..  (2008)  Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties..  Bioorg Med Chem Lett,  18  (20): (5439-5442).  [PMID:18805692]
33. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107]
34. Donohue SR, Pike VW, Finnema SJ, Truong P, Andersson J, Gulyás B, Halldin C..  (2008)  Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors..  J Med Chem,  51  (18): (5608-5616).  [PMID:18754613]
35. Lazarova N, Zoghbi SS, Hong J, Seneca N, Tuan E, Gladding RL, Liow JS, Taku A, Innis RB, Pike VW..  (2008)  Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function..  J Med Chem,  51  (19): (6034-6043).  [PMID:18783208]
36. Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, Lindsley CW, Rittle KE, Bock MG, Hartman GD, Uebele VN, Nuss CE, Fox SV, Kraus RL, Doran SM, Connolly TM, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Marino MJ, Graufelds VK, DiLella AG, Reynolds IJ, Vargas HM, Bunting PB, Woltmann RF, Magee MM, Koblan KS, Renger JJ..  (2008)  Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels..  J Med Chem,  51  (20): (6471-6477).  [PMID:18817368]
37. Vu CB, Bemis JE, Disch JS, Ng PY, Nunes JJ, Milne JC, Carney DP, Lynch AV, Smith JJ, Lavu S, Lambert PD, Gagne DJ, Jirousek MR, Schenk S, Olefsky JM, Perni RB..  (2009)  Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators..  J Med Chem,  52  (5): (1275-1283).  [PMID:19199480]
38. Miller NR, Daniels RN, Bridges TM, Brady AE, Conn PJ, Lindsley CW..  (2008)  Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen..  Bioorg Med Chem Lett,  18  (20): (5443-5447).  [PMID:18829311]
39. Liu F, Chen X, Allali-Hassani A, Quinn AM, Wasney GA, Dong A, Barsyte D, Kozieradzki I, Senisterra G, Chau I, Siarheyeva A, Kireev DB, Jadhav A, Herold JM, Frye SV, Arrowsmith CH, Brown PJ, Simeonov A, Vedadi M, Jin J..  (2009)  Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a..  J Med Chem,  52  (24): (7950-7953).  [PMID:19891491]
40. Donohue SR, Varnäs K, Jia Z, Gulyás B, Pike VW, Halldin C..  (2009)  Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors..  Bioorg Med Chem Lett,  19  (21): (6209-6212).  [PMID:19767206]
41. Xu R, Hong J, Morse CL, Pike VW..  (2010)  Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography..  J Med Chem,  53  (19): (7035-7047).  [PMID:20812727]
42. Hooker JM, Kim SW, Reibel AT, Alexoff D, Xu Y, Shea C..  (2010)  Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates..  Bioorg Med Chem,  18  (22): (7739-7745).  [PMID:20451398]
43. Siméon FG, Wendahl MT, Pike VW..  (2011)  Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging..  J Med Chem,  54  (3): (901-908).  [PMID:21207959]
44. Donohue SR, Dannals RF, Halldin C, Pike VW..  (2011)  N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors..  J Med Chem,  54  (8): (2961-2970).  [PMID:21428406]
45. Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M..  (2011)  Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist..  J Med Chem,  54  (13): (4781-4792).  [PMID:21634396]
46. Mésangeau C, Amata E, Alsharif W, Seminerio MJ, Robson MJ, Matsumoto RR, Poupaert JH, McCurdy CR..  (2011)  Synthesis and pharmacological evaluation of indole-based sigma receptor ligands..  Eur J Med Chem,  46  (10): (5154-5161).  [PMID:21899931]
47. Lebois EP, Digby GJ, Sheffler DJ, Melancon BJ, Tarr JC, Cho HP, Miller NR, Morrison R, Bridges TM, Xiang Z, Daniels JS, Wood MR, Conn PJ, Lindsley CW..  (2011)  Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071..  Bioorg Med Chem Lett,  21  (21): (6451-6455).  [PMID:21930376]
48. Melancon BJ, Lamers AP, Bridges TM, Sulikowski GA, Utley TJ, Sheffler DJ, Noetzel MJ, Morrison RD, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Wood MR..  (2012)  Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012..  Bioorg Med Chem Lett,  22  (2): (1044-1048).  [PMID:22197142]
49. Hanrahan P, Bell J, Bottomley G, Bradley S, Clarke P, Curtis E, Davis S, Dawson G, Horswill J, Keily J, Moore G, Rasamison C, Bloxham J..  (2012)  Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity..  Bioorg Med Chem Lett,  22  (6): (2271-2278).  [PMID:22342626]
50. Sun X, Qiu J, Strong SA, Green LS, Wasley JW, Blonder JP, Colagiovanni DB, Stout AM, Mutka SC, Richards JP, Rosenthal GJ..  (2012)  Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: carboxamide modification..  Bioorg Med Chem Lett,  22  (6): (2338-2342).  [PMID:22342142]
51. Melancon BJ, Gogliotti RD, Tarr JC, Saleh SA, Chauder BA, Lebois EP, Cho HP, Utley TJ, Sheffler DJ, Bridges TM, Morrison RD, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Wood MR..  (2012)  Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor..  Bioorg Med Chem Lett,  22  (10): (3467-3472).  [PMID:22507963]
52. Zhang H, Tückmantel W, Eaton JB, Yuen PW, Yu LF, Bajjuri KM, Fedolak A, Wang D, Ghavami A, Caldarone B, Paterson NE, Lowe DA, Brunner D, Lukas RJ, Kozikowski AP..  (2012)  Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile..  J Med Chem,  55  (2): (717-724).  [PMID:22171543]
53. Bao X, Lu S, Liow JS, Zoghbi SS, Jenko KJ, Clark DT, Gladding RL, Innis RB, Pike VW..  (2012)  Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype..  J Med Chem,  55  (5): (2406-2415).  [PMID:22313227]
54. Salovich JM, Vinson PN, Sheffler DJ, Lamsal A, Utley TJ, Blobaum AL, Bridges TM, Le U, Jones CK, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR..  (2012)  Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor..  Bioorg Med Chem Lett,  22  (15): (5084-5088).  [PMID:22738637]
55. Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB..  (2012)  ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis..  J Med Chem,  55  (1): (515-527).  [PMID:22191331]
56. Poslusney MS, Sevel C, Utley TJ, Bridges TM, Morrison RD, Kett NR, Sheffler DJ, Niswender CM, Daniels JS, Conn PJ, Lindsley CW, Wood MR..  (2012)  Synthesis and biological characterization of a series of novel diaryl amide M₁ antagonists..  Bioorg Med Chem Lett,  22  (22): (6923-6928).  [PMID:23062550]
57. James ML, Shen B, Zavaleta CL, Nielsen CH, Mesangeau C, Vuppala PK, Chan C, Avery BA, Fishback JA, Matsumoto RR, Gambhir SS, McCurdy CR, Chin FT..  (2012)  New positron emission tomography (PET) radioligand for imaging σ-1 receptors in living subjects..  J Med Chem,  55  (19): (8272-8282).  [PMID:22853801]
58. Sidique S, Dhanya RP, Sheffler DJ, Nickols HH, Yang L, Dahl R, Mangravita-Novo A, Smith LH, D'Souza MS, Semenova S, Conn PJ, Markou A, Cosford ND..  (2012)  Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence..  J Med Chem,  55  (22): (9434-9445).  [PMID:23009245]
59. Annedi SC, Maddaford SP, Ramnauth J, Renton P, Rybak T, Silverman S, Rakhit S, Mladenova G, Dove P, Andrews JS, Zhang D, Porreca F..  (2012)  Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine..  Eur J Med Chem,  55  (94-107).  [PMID:22840695]
60. Le U, Melancon BJ, Bridges TM, Vinson PN, Utley TJ, Lamsal A, Rodriguez AL, Venable D, Sheffler DJ, Jones CK, Blobaum AL, Wood MR, Daniels JS, Conn PJ, Niswender CM, Lindsley CW, Hopkins CR..  (2013)  Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia..  Bioorg Med Chem Lett,  23  (1): (346-350).  [PMID:23177787]
61. Sheffler DJ, Sevel C, Le U, Lovell KM, Tarr JC, Carrington SJ, Cho HP, Digby GJ, Niswender CM, Conn PJ, Hopkins CR, Wood MR, Lindsley CW..  (2013)  Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism..  Bioorg Med Chem Lett,  23  (1): (223-227).  [PMID:23200253]
62. Zheng G, Smith AM, Huang X, Subramanian KL, Siripurapu KB, Deaciuc A, Zhan CG, Dwoskin LP..  (2013)  Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists..  J Med Chem,  56  (4): (1693-1703).  [PMID:23379472]
63. Germain AR, Carmody LC, Nag PP, Morgan B, Verplank L, Fernandez C, Donckele E, Feng Y, Perez JR, Dandapani S, Palmer M, Lander ES, Gupta PB, Schreiber SL, Munoz B..  (2013)  Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells..  Bioorg Med Chem Lett,  23  (6): (1834-1838).  [PMID:23403082]
64. Santangelo Freel RM, Ogden KK, Strong KL, Khatri A, Chepiga KM, Jensen HS, Traynelis SF, Liotta DC..  (2013)  Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors..  J Med Chem,  56  (13): (5351-5381).  [PMID:23627311]
65. Cui JJ, Shen H, Tran-Dubé M, Nambu M, McTigue M, Grodsky N, Ryan K, Yamazaki S, Aguirre S, Parker M, Li Q, Zou H, Christensen J..  (2013)  Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats..  J Med Chem,  56  (17): (6651-6665).  [PMID:23944843]
66. Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML..  (2013)  New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo..  J Med Chem,  56  (20): (7851-7861).  [PMID:24050112]
67. Xu R, Zanotti-Fregonara P, Zoghbi SS, Gladding RL, Woock AE, Innis RB, Pike VW..  (2013)  Synthesis and evaluation in monkey of [(18)F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([(18)F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1)..  J Med Chem,  56  (22): (9146-9155).  [PMID:24147864]
68. Williams DA, Zaidi SA, Zhang Y..  (2014)  5-Hydroxy-2-(2-phenylethyl)chromone (5-HPEC): a novel non-nitrogenous ligand for 5-HT2B receptor..  Bioorg Med Chem Lett,  24  (6): (1489-1492).  [PMID:24582985]
69. Gessier F, Preuss I, Yin H, Rosenkilde MM, Laurent S, Endres R, Chen YA, Marsilje TH, Seuwen K, Nguyen DG, Sailer AW..  (2014)  Identification and characterization of small molecule modulators of the Epstein-Barr virus-induced gene 2 (EBI2) receptor..  J Med Chem,  57  (8): (3358-3368).  [PMID:24678947]
70. Dhanya RP, Sheffler DJ, Dahl R, Davis M, Lee PS, Yang L, Nickols HH, Cho HP, Smith LH, D'Souza MS, Conn PJ, Der-Avakian A, Markou A, Cosford ND..  (2014)  Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence..  J Med Chem,  57  (10): (4154-4172).  [PMID:24735492]
71. Kołaczkowski M, Marcinkowska M, Bucki A, Pawłowski M, Mitka K, Jaśkowska J, Kowalski P, Kazek G, Siwek A, Wasik A, Wesołowska A, Mierzejewski P, Bienkowski P..  (2014)  Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia..  J Med Chem,  57  (11): (4543-4557).  [PMID:24805037]
72. Schroeder CE, Yao T, Sotsky J, Smith RA, Roy S, Chu YK, Guo H, Tower NA, Noah JW, McKellip S, Sosa M, Rasmussen L, Smith LH, White EL, Aubé J, Jonsson CB, Chung D, Golden JE..  (2014)  Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus..  J Med Chem,  57  (20): (8608-8621).  [PMID:25244572]
73. Takai K, Inoue Y, Konishi Y, Suwa A, Uruno Y, Matsuda H, Nakako T, Sakai M, Nishikawa H, Hashimoto G, Enomoto T, Kitamura A, Uematsu Y, Kiyoshi A, Sumiyoshi T..  (2014)  Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists..  Bioorg Med Chem Lett,  24  (14): (3189-3193).  [PMID:24856064]
74. Sampson D, Bricker B, Zhu XY, Peprah K, Lamango NS, Setola V, Roth BL, Ablordeppey SY..  (2014)  Further evaluation of the tropane analogs of haloperidol..  Bioorg Med Chem Lett,  24  (17): (4294-4297).  [PMID:25070422]
75. Huang M, Suk DH, Cho NC, Bhattarai D, Kang SB, Kim Y, Pae AN, Rhim H, Keum G..  (2015)  Synthesis and biological evaluation of isoxazoline derivatives as potent M₁ muscarinic acetylcholine receptor agonists..  Bioorg Med Chem Lett,  25  (7): (1546-1551).  [PMID:25765911]
76. Kapadia N, Harding WW..  (2015)  C4 phenyl aporphines with selective h5-HT(2B) receptor affinity..  Bioorg Med Chem Lett,  25  (17): (3451-3454).  [PMID:26227772]
77. Ponnala S, Kapadia N, Madapa S, Alberts IL, Harding WW..  (2015)  Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor..  Bioorg Med Chem Lett,  25  (22): (5102-5106).  [PMID:26475518]
78. Nirogi R, Mohammed AR, Shinde AK, Bogaraju N, Gagginapalli SR, Ravella SR, Kota L, Bhyrapuneni G, Muddana NR, Benade V, Palacharla RC, Jayarajan P, Subramanian R, Goyal VK..  (2015)  Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease..  Eur J Med Chem,  103  (289-301).  [PMID:26363507]
79. Lopez-Tapia F, Walker KA, Brotherton-Pleiss C, Caroon J, Nitzan D, Lowrie L, Gleason S, Zhao SH, Berger J, Cockayne D, Phippard D, Suttmann R, Fitch WL, Bourdet D, Rege P, Huang X, Broadbent S, Dvorak C, Zhu J, Wagner P, Padilla F, Loe B, Jahangir A, Alker A..  (2015)  Novel Series of Dihydropyridinone P2X7 Receptor Antagonists..  J Med Chem,  58  (21): (8413-8426).  [PMID:26460788]
80. Huard K, Gosset JR, Montgomery JI, Gilbert A, Hayward MM, Magee TV, Cabral S, Uccello DP, Bahnck K, Brown J, Purkal J, Gorgoglione M, Lanba A, Futatsugi K, Herr M, Genung NE, Aspnes G, Polivkova J, Garcia-Irizarry CN, Li Q, Canterbury D, Niosi M, Vera NB, Li Z, Khunte B, Siderewicz J, Rolph T, Erion DM..  (2016)  Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family..  J Med Chem,  59  (3): (1165-1175).  [PMID:26734723]
81. Waszkielewicz AM, Gunia-Krzyżak A, Powroźnik B, Słoczyńska K, Pękala E, Walczak M, Bednarski M, Żesławska E, Nitek W, Marona H..  (2016)  Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents..  Bioorg Med Chem,  24  (8): (1793-1810).  [PMID:26988801]
82. Blanco MJ, Vetman T, Chandrasekhar S, Fisher MJ, Harvey A, Kuklish SL, Chambers M, Lin C, Mudra D, Oskins J, Wang XS, Yu XP, Warshawsky AM..  (2016)  Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists..  Bioorg Med Chem Lett,  26  (9): (2303-2307).  [PMID:27020304]
83. Wood MR, Noetzel MJ, Engers JL, Bollinger KA, Melancon BJ, Tarr JC, Han C, West M, Gregro AR, Lamsal A, Chang S, Ajmera S, Smith E, Chase P, Hodder PS, Bubser M, Jones CK, Hopkins CR, Emmitte KA, Niswender CM, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW..  (2016)  Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core..  Bioorg Med Chem Lett,  26  (13): (3029-3033).  [PMID:27185330]
84. Wood MR, Noetzel MJ, Poslusney MS, Melancon BJ, Tarr JC, Lamsal A, Chang S, Luscombe VB, Weiner RL, Cho HP, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW..  (2017)  Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs..  Bioorg Med Chem Lett,  27  (2): (171-175).  [PMID:27939174]
85. Bender AM, Weiner RL, Luscombe VB, Cho HP, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW..  (2017)  Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype..  Bioorg Med Chem Lett,  27  (11): (2479-2483).  [PMID:28427812]
86. Fish I, Stößel A, Eitel K, Valant C, Albold S, Huebner H, Möller D, Clark MJ, Sunahara RK, Christopoulos A, Shoichet BK, Gmeiner P..  (2017)  Structure-Based Design and Discovery of New M2 Receptor Agonists..  J Med Chem,  60  (22): (9239-9250).  [PMID:29094937]
87. Wu CH, Song JS, Kuan HH, Wu SH, Chou MC, Jan JJ, Tsou LK, Ke YY, Chen CT, Yeh KC, Wang SY, Yeh TK, Tseng CT, Huang CL, Wu MH, Kuo PC, Lee CJ, Shia KS..  (2018)  Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond..  J Med Chem,  61  (3): (818-833).  [PMID:29314840]
88. Melancon BJ, Wood MR, Noetzel MJ, Nance KD, Engelberg EM, Han C, Lamsal A, Chang S, Cho HP, Byers FW, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Wu D, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW..  (2017)  Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology..  Bioorg Med Chem Lett,  27  (11): (2296-2301).  [PMID:28442253]
89. Tarr JC, Wood MR, Noetzel MJ, Bertron JL, Weiner RL, Rodriguez AL, Lamsal A, Byers FW, Chang S, Cho HP, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW..  (2017)  Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides..  Bioorg Med Chem Lett,  27  (13): (2990-2995).  [PMID:28522253]
90. Bender AM, Weiner RL, Luscombe VB, Ajmera S, Cho HP, Chang S, Zhan X, Rodriguez AL, Niswender CM, Engers DW, Bridges TM, Conn PJ, Lindsley CW..  (2017)  Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists..  Bioorg Med Chem Lett,  27  (15): (3576-3581).  [PMID:28633897]
91. Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T..  (2018)  Identification and biological evaluation of thiazole-based inverse agonists of RORγt..  Bioorg Med Chem Lett,  28  (9): (1446-1455).  [PMID:29631962]
92. Liu Z, Tian B, Chen H, Wang P, Brasier AR, Zhou J..  (2018)  Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation..  Eur J Med Chem,  151  (450-461).  [PMID:29649741]
93. Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW..  (2017)  Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides..  Bioorg Med Chem Lett,  27  (23): (5179-5184).  [PMID:29089231]
94. Sowaileh MF, Salyer AE, Roy KK, John JP, Woods JR, Doerksen RJ, Hockerman GH, Colby DA..  (2018)  Agonists of the γ-aminobutyric acid type B (GABAB) receptor derived from β-hydroxy and β-amino difluoromethyl ketones..  Bioorg Med Chem Lett,  28  (16): (2697-2700).  [PMID:29657102]
95. Amato G, Manke A, Wiethe R, Vasukuttan V, Snyder R, Yueh YL, Decker A, Runyon S, Maitra R..  (2019)  Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor..  J Med Chem,  62  (13): (6330-6345).  [PMID:31185168]
96. Bachovchin KA, Sharma A, Bag S, Klug DM, Schneider KM, Singh B, Jalani HB, Buskes MJ, Mehta N, Tanghe S, Momper JD, Sciotti RJ, Rodriguez A, Mensa-Wilmot K, Pollastri MP, Ferrins L..  (2019)  Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development..  J Med Chem,  62  (2): (665-687).  [PMID:30565932]
97. Martini ML, Liu J, Ray C, Yu X, Huang XP, Urs A, Urs N, McCorvy JD, Caron MG, Roth BL, Jin J..  (2019)  Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D1 Receptor Agonists..  J Med Chem,  62  (7): (3753-3772).  [PMID:30875219]
98. Ti H, Zhou Y, Liang X, Li R, Ding K, Zhao X..  (2019)  Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)..  J Med Chem,  62  (13): (5944-5978).  [PMID:30682248]
99. Geanes AR, Cho HP, Nance KD, McGowan KM, Conn PJ, Jones CK, Meiler J, Lindsley CW..  (2016)  Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes..  Bioorg Med Chem Lett,  26  (18): (4487-4491).  [PMID:27503678]
100. Schrader TO,Xiong Y,Lorenzana AO,Broadhead A,Stebbins KJ,Poon MM,Baccei C,Lorrain DS.  (2021)  Discovery of PIPE-359, a Brain-Penetrant, Selective M Receptor Antagonist with Robust Efficacy in Murine MOG-EAE..  ACS Med Chem Lett,  12  (1): (155-161).  [PMID:33488977]
101. Cunha, Micael Rodrigues, Bhardwaj, Rajesh, Carrel, Aline Lucie, Lindinger, Sonja, Romanin, Christoph, Parise-Filho, Roberto, Hediger, Matthias A., Reymond, Jean-Louis.  (2020)  Natural product inspired optimization of a selective TRPV6 calcium channel inhibitor.  RSC Med Chem,  11  (9): (1032-1040).  [PMID:33479695]
102. Wang P,Felsing DE,Chen H,Stutz SJ,Murphy RE,Cunningham KA,Allen JA,Zhou J.  (2020)  Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior..  J Med Chem,  63  (22): (13951-13972).  [PMID:33198466]
103. Urabe H,Miyakoshi N,Ohtake N,Nozoe A,Ochi M,Fukasawa M,Kinoshita K,Yamaguchi JI,Marumo T,Hikichi H,Chaki S,Hashihayata T.  (2020)  Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability..  Eur J Med Chem,  203  (112521-112521).  [PMID:32698110]
104. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ..  (2002)  TTD: Therapeutic Target Database..  Nucleic acids research,    (1):   [PMID:11752352]
105. Wang, Jen C JC and 21 more authors..  (2004)  Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome..  Human molecular genetics,    (1):   [PMID:15229186]
106. Renner, Ulf D UD, Oertel, Reinhard R and Kirch, Wilhelm W..  (2005)  Pharmacokinetics and pharmacodynamics in clinical use of scopolamine..  Therapeutic drug monitoring,      [PMID:16175141]
107. Zuchner, Thole T, Schliebs, Reinhard R and Perez-Polo, J Regino JR..  (2005)  Down-regulation of muscarinic acetylcholine receptor M2 adversely affects the expression of Alzheimer's disease-relevant genes and proteins..  Journal of neurochemistry,      [PMID:16181410]
108. Leong, Wai Fook WF and Chow, Vincent T K VT..  (2006)  Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection..  Cellular microbiology,      [PMID:16548883]
109. Abrams, Paul P and Andersson, Karl-Erik KE..  (2007)  Muscarinic receptor antagonists for overactive bladder..  BJU international,      [PMID:17922784]
110. Jha, Swati and Parsons, Matthew..  (2006)  Treatment of overactive bladder in the aging population: focus on darifenacin..  Clinical interventions in aging,      [PMID:18046909]
111. Figueroa, Katherine W; Griffin, Michael T and Ehlert, Frederick J..  (2009)  Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes..  The Journal of pharmacology and experimental therapeutics,      [PMID:18824613]
112. Milchert, M M and 9 more authors..  (2009)  Skeletal muscle relaxants inhibit rat tracheal smooth muscle tone in vitro..  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society,      [PMID:20400785]
113. Reiner, Cindy L CL and 5 more authors..  (2010)  RACK1 associates with muscarinic receptors and regulates M(2) receptor trafficking..  PloS one,    (20):   [PMID:20976005]
114. Castro, Juciane Maria de Andrade and 10 more authors..  (2013)  Role of m2 muscarinic receptor in the airway response to methacholine of mice selected for minimal or maximal acute inflammatory response..  BioMed research international,      [PMID:23691511]
115. Brafford, Megan V and Glode, Ashley..  (2014)  Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting..  Journal of the advanced practitioner in oncology,      [PMID:25032030]
116. de Bartolomeis, Andrea A, Tomasetti, Carmine C and Iasevoli, Felice F..  (2015)  Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism..  CNS drugs,      [PMID:26346901]
117. Qi, Wei W and 39 more authors..  (2017)  An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED..  Nature chemical biology,      [PMID:28135235]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.